AOD-9604 vs Tirzepatide: A Research Reference
AOD-9604 and Tirzepatide are routinely cross-referenced by researchers scoping a literature review. The two records are not equivalent.
Compound profiles
AOD-9604 in the indexed record
Indexed output for AOD-9604 stands at 16 records, a limited literature with no registered studies currently listed on ClinicalTrials.gov.
Journals represented in the current index include Curr Opin Investig Drugs, Drug Test Anal, Expert Rev Proteomics, spanning 2004–2026.
- AOD-9604 Metabolic — Curr Opin Investig Drugs, 2004. PMID: 15134286
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- AOD-9604 does not influence the WADA hGH isoform immunoassay — Drug Test Anal, 2013. PMID: 24124033
- Human sports drug testing by mass spectrometry — Mass Spectrom Rev, 2017. PMID: 26213263
Tirzepatide in the indexed record
Searching Tirzepatide against the PubMed index returns 2,492 records, a substantial evidence base, alongside 297 registered studies on ClinicalTrials.gov.
Journals represented in the current index include J Am Pharm Assoc (2003).
- The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception — J Am Pharm Assoc (2003), 2024. PMID: 37940101
Side-by-side research profile
| Parameter | AOD-9604 | Tirzepatide |
|---|---|---|
| PubMed indexed records | 16 | 2,492 |
| Registered studies (ClinicalTrials.gov) | 0 | 297 |
| Literature depth | Emerging | Extensive |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
AOD-9604 and Tirzepatide sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for AOD-9604 describes conditions validated for AOD-9604: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Tirzepatide without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
How the literature differs
The indexed record is not symmetrical between these two compounds. Tirzepatide carries 2,476 more indexed records than AOD-9604, which means published methodology, characterisation data and replication attempts are more readily located for Tirzepatide. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (0 vs 297) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Selecting between them for a study design
AOD-9604 and Tirzepatide are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Tirzepatide) generally offers more methodological precedent.
Documentation standards
Identity and purity are separate claims requiring separate methods. A purity percentage quoted without the analytical method behind it, or a certificate with no lot reference, is a documentation gap rather than verification.
Frequently asked questions
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Are AOD-9604 and Tirzepatide the same compound?
No. They are structurally distinct research compounds with separate literature records — 16 indexed records for AOD-9604 and 2,492 for Tirzepatide.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Related references
- AOD-9604 — product and lot documentation
- Tirzepatide — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.